Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

L. Hovorkova, M. Zaliova, NC. Venn, K. Bleckmann, M. Trkova, E. Potuckova, M. Vaskova, J. Linhartova, K. Machova Polakova, E. Fronkova, W. Muskovic, JE. Giles, PJ. Shaw, G. Cario, R. Sutton, J. Stary, J. Trka, J. Zuna,

. 2017 ; 129 (20) : 2771-2781. [pub] 20170322

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17030938

Grant support
NV15-31540A MZ0 CEP Register
NV16-30186A MZ0 CEP Register

We used the genomic breakpoint between BCR and ABL1 genes for the DNA-based monitoring of minimal residual disease (MRD) in 48 patients with childhood acute lymphoblastic leukemia (ALL). Comparing the results with standard MRD monitoring based on immunoglobulin/T-cell receptor (Ig/TCR) gene rearrangements and with quantification of IKZF1 deletion, we observed very good correlation for the methods in a majority of patients; however, >20% of children (25% [8/32] with minor and 12.5% [1/8] with major-BCR-ABL1 variants in the consecutive cohorts) had significantly (>1 log) higher levels of BCR-ABL1 fusion than Ig/TCR rearrangements and/or IKZF1 deletion. We performed cell sorting of the diagnostic material and assessed the frequency of BCR-ABL1-positive cells in various hematopoietic subpopulations; 12% to 83% of non-ALL B lymphocytes, T cells, and/or myeloid cells harbored the BCR-ABL1 fusion in patients with discrepant MRD results. The multilineage involvement of the BCR-ABL1-positive clone demonstrates that in some patients diagnosed with BCR-ABL1-positive ALL, a multipotent hematopoietic progenitor is affected by the BCR-ABL1 fusion. These patients have BCR-ABL1-positive clonal hematopoiesis resembling a chronic myeloid leukemia (CML)-like disease manifesting in "lymphoid blast crisis." The biological heterogeneity of BCR-ABL1-positive ALL may impact the patient outcomes and optimal treatment (early stem cell transplantation vs long-term administration of tyrosine-kinase inhibitors) as well as on MRD testing. Therefore, we recommend further investigations on CML-like BCR-ABL1-positive ALL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030938
003      
CZ-PrNML
005      
20201104153344.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2016-11-749978 $2 doi
035    __
$a (PubMed)28331056
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hovorkova, Lenka $u Childhood Leukemia Investigation Prague (CLIP) and. Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology / $c L. Hovorkova, M. Zaliova, NC. Venn, K. Bleckmann, M. Trkova, E. Potuckova, M. Vaskova, J. Linhartova, K. Machova Polakova, E. Fronkova, W. Muskovic, JE. Giles, PJ. Shaw, G. Cario, R. Sutton, J. Stary, J. Trka, J. Zuna,
520    9_
$a We used the genomic breakpoint between BCR and ABL1 genes for the DNA-based monitoring of minimal residual disease (MRD) in 48 patients with childhood acute lymphoblastic leukemia (ALL). Comparing the results with standard MRD monitoring based on immunoglobulin/T-cell receptor (Ig/TCR) gene rearrangements and with quantification of IKZF1 deletion, we observed very good correlation for the methods in a majority of patients; however, >20% of children (25% [8/32] with minor and 12.5% [1/8] with major-BCR-ABL1 variants in the consecutive cohorts) had significantly (>1 log) higher levels of BCR-ABL1 fusion than Ig/TCR rearrangements and/or IKZF1 deletion. We performed cell sorting of the diagnostic material and assessed the frequency of BCR-ABL1-positive cells in various hematopoietic subpopulations; 12% to 83% of non-ALL B lymphocytes, T cells, and/or myeloid cells harbored the BCR-ABL1 fusion in patients with discrepant MRD results. The multilineage involvement of the BCR-ABL1-positive clone demonstrates that in some patients diagnosed with BCR-ABL1-positive ALL, a multipotent hematopoietic progenitor is affected by the BCR-ABL1 fusion. These patients have BCR-ABL1-positive clonal hematopoiesis resembling a chronic myeloid leukemia (CML)-like disease manifesting in "lymphoid blast crisis." The biological heterogeneity of BCR-ABL1-positive ALL may impact the patient outcomes and optimal treatment (early stem cell transplantation vs long-term administration of tyrosine-kinase inhibitors) as well as on MRD testing. Therefore, we recommend further investigations on CML-like BCR-ABL1-positive ALL.
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    12
$a zlomy chromozomů $7 D019457
650    _2
$a bcr-abl fúzní proteiny $x genetika $7 D016044
650    _2
$a delece genu $7 D017353
650    12
$a genom lidský $7 D015894
650    _2
$a hematopoéza $7 D006410
650    _2
$a lidé $7 D006801
650    _2
$a transkripční faktor Ikaros $x genetika $7 D051740
650    _2
$a chronická myeloidní leukemie $x krev $x genetika $7 D015464
650    _2
$a počet leukocytů $7 D007958
650    _2
$a reziduální nádor $x genetika $7 D018365
650    _2
$a akutní lymfatická leukemie $x krev $x genetika $7 D054198
650    _2
$a receptory antigenů T-buněk $x genetika $7 D011948
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zaliova, Marketa $u Childhood Leukemia Investigation Prague (CLIP) and. Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. University Hospital Motol, Prague, Czech Republic.
700    1_
$a Venn, Nicola C $u Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.
700    1_
$a Bleckmann, Kirsten $u Department of Pediatrics, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany.
700    1_
$a Trkova, Marie $u Gennet, Center for Fetal Medicine and Reproductive Genetics, Prague, Czech Republic.
700    1_
$a Potuckova, Eliska $u Childhood Leukemia Investigation Prague (CLIP) and. Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Vaskova, Martina $u Childhood Leukemia Investigation Prague (CLIP) and. Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Linhartova, Jana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Machova Polakova, Katerina $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Fronkova, Eva $u Childhood Leukemia Investigation Prague (CLIP) and. Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Muskovic, Walter $u Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.
700    1_
$a Giles, Jodie E $u Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.
700    1_
$a Shaw, Peter J $u Blood and Marrow Transplant Services, Children's Hospital at Westmead, Sydney, NSW, Australia; and.
700    1_
$a Cario, Gunnar $u Department of Pediatrics, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany.
700    1_
$a Sutton, Rosemary $u Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia. School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.
700    1_
$a Stary, Jan $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. University Hospital Motol, Prague, Czech Republic.
700    1_
$a Trka, Jan $u Childhood Leukemia Investigation Prague (CLIP) and. Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. University Hospital Motol, Prague, Czech Republic.
700    1_
$a Zuna, Jan $u Childhood Leukemia Investigation Prague (CLIP) and. Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. University Hospital Motol, Prague, Czech Republic.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 129, č. 20 (2017), s. 2771-2781
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28331056 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20201104153342 $b ABA008
999    __
$a ok $b bmc $g 1254531 $s 991965
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 129 $c 20 $d 2771-2781 $e 20170322 $i 1528-0020 $m Blood $n Blood $x MED00000807
GRA    __
$a NV15-31540A $p MZ0
GRA    __
$a NV16-30186A $p MZ0
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Archiving options